Pharmamarketeer
wet- en regelgeving

EMA committee recommends marketing approval for Pfizer’s biosimilar, Zirabev

17 december 2018
Pharma Biz

Pfizer Inc, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for Zirabev (bevacizumab), a potential biosimilar to Avastin (bevacizumab), is Pfizer’s second therapeutic oncology biosimilar to receive a positive CHMP opinion in Europe in 2018.

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)